Search

This brief describes current law related to coverage and payment for dental services under Medicare and the rationale for changes to current policy, explains changes to dental payment and coverage included in the 2023 and 2024 final rules, and discusses the impact on Medicare and beneficiaries. These rules modestly expand the types of dental services that are covered under Medicare, but do not represent a broad expansion of Medicare coverage of dental services and will not substantially increase Medicare spending or covered dental services for a large number of Medicare beneficiaries.

This brief examines how Part D enrollees’ access to and utilization of the first set of 10 selected drugs could be affected by the new Part D coverage and formulary requirements for selected drugs established by the Inflation Reduction Act and in CMS guidance, as well as the potential for lower out-of-pocket costs.

The Affordable Care Act (ACA) requires new private health insurance plans to cover many recommended preventive services without any patient cost-sharing. This tracker presents up-to-date information on the adult preventive services nongrandfathered private plans must cover, by condition, including a summary of the recommendation, the target population, the effective date of coverage, and related federal coverage clarifications.

This fact sheet identifies key U.S. government global health positions and officials.

This brief discusses Medicaid coverage of weight-loss drugs, recent trends in Medicaid utilization and gross spending on new drugs used for weight loss, and the potential implications of those new drugs for Medicaid programs and enrollees.

Firearms were responsible for 20 percent of all child and teen deaths in the U.S. for both 2020 and 2021, compared to an average of less than 2 percent in similarly large and wealthy nations. This puts the U.S. far ahead of peer nations in child and teen firearm deaths.

This policy watch discusses some of the potential implications of the new anti-obesity drugs for racial equity.

The Inflation Reduction Act requires the federal government to negotiate the price of certain high-spending drugs covered by Medicare. This analysis provides context for understanding the potential impact of negotiating prices for a limited number of Medicare-covered drugs by identifying the 10 top-selling Part D drugs in 2021, measuring the share of total Part D drug spending accounted for by top-selling drugs that year, and examining changes in spending and use of these drugs since 2018.

This fact sheet explores the history, funding, and future outlook of the President’s Emergency Plan for AIDS Relief (PEPFAR), the U.S. government’s major global initiative to combat HIV/AIDS.